Supplementary Figure 8: S-CAP test-set performance resembles performance during cross-validation.
From: S-CAP extends pathogenicity prediction to genetic variants that affect RNA splicing
The cross validation performance is measured over benign and pathogenic training variants as described in column 1 in Table 3. The cross validation performance is measured as the mean performance over all 5 folds. We find the performance is similar to between the cross validation and the test set reported performance in all 6 regions.
